Spectrophotometric method for the estimation of Atorvastatin calcium in pharmaceutical preparation

 

S. Subramanya Raj Urs*, Gangambika H.M., Rajashekara Murthy M., Asharani D.R.

Post Graduate Department of Chemistry, JSS College for Women, Sarawathipuram, Mysuru 570 009

*Corresponding Author E-mail: ssrajurs@yahoo.co.in

 

ABSTRACT:

Present study describes development and validation of UV-Spectrophotometric method for the estimation of Atorvastatin Calcium in pharmaceutical preparation. During development of analytical methods, methanol and hydrotropic solubilization reagent is employed to enhance aqueous solubility of poorly water soluble Atovastatin Calcium in dosage forms. In the proposed methods 2M Urea and 2M Thiourea solution is used as hydrotropic solubilizing agent. Absorption maxima was determined with 10μg/ml solution by scanning in the range 200-400nm. Standard stock solution prepared in methanol (λmax:247nm) and hydrotropic solubilization agent in water(λmax:240nm). The proposed methods obeys Beer’s law in the range 5-40 μg/ml. The methods were validated in terms of Linearity, Precision and Accuracy. Results of analysis were validated statistically and by recovery studies. It was observed that there is no interference of impurities or excipients during the estimation of drug. This shows the adoptability of the methods for routine analysis of drugs in marketed formulations in quality control laboratories.

 

KEYWORDS:

 

 

INTRODUCTION:

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Atorvastatin calcium is a member of the drug class known as statins, used for lowering blood cholesterol chemically, it is (3R, 5R)-7-(2-(4-fluropenyl) -3-phenyl-4- (phenylcarbamoy1)-5-propan- 2ylpyrrol -1-yl)-3, 5-dihydroxyheptanoicacid, it works by inhibiting 3-hydroxy 3-methyl glutaryl co-enzyme (HMG-CoA) reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body.

 

The primary use of atorvastatin are for the treatment of dyslipidemia and the prevention of cardiovascular disease. It is recommended to be used only after other measures such as diet, exercise and weight reduction have no time proved cholesterol levels. It is used in hyper cholesterolemia to reduce total cholesterol, low density lipoprotein-c. Apolipoprotein-B and triglycerides levels.

 

A survey of literature revealed that analytical methods like HPLC, HPTLC are reported for determination of Atorvastatin calcium individually and with other drug combination. Few HPLC, Mass spectroscopy, HPTLC Methods were reported for determination of atorvastatin calcium. Several studies have been reported for the determination of Atorvastatin in pharmaceutical and biological fluids including spectrophotometric methods (1,2), electrophoresis (3,4), polarographic methods (5) and chromatographic methods with different detectors (6,7). There are many reported methods for the determination of Atorvastatin alone (8,9), in combination with other drugs in pharmaceutical dosage forms (10,11) ,different LC Methods(12, 13), spectrophotometric methods(14-16), capillary electrophoresis (17), HPTLC (18) have been reported for the estimation of the Atorvastatin in their mixture.

 

Detailed survey of literature for Atorvastatin revealed several methods based on different techniques (19, 20) like HPLC and LC-MS for its determination in plasma serum and human serum and pharmaceutical formulation. The reported HPLC method involves costly sophisticated instrumentation and time consuming process while HPTLC method has no reproducibility. In the analysis of atorvastatin, major problem is solubilisation of Atorvastatin in most of solvents during analysis. Quantitative estimation of poorly water soluble drugs involves use of organic solvents. Major drawbacks of organic solvents include hige cost volatility and toxicity. Syed Najmul Hejaz Azmi et al (21) have reported HPLC –UV method for the determination of atorvastatin and pooja A chawla et al (22) have reported a review on various analytical methods for the analysis of atorvastatin.

 

Literature survey revealed that no simple UV method has been reported to the best of our knowledge. so emphasis was given to develop simple, sensitive, selective, precise and accurate UV method for determination of atorvastatin calcium, therefore in the proposed methods 2M urea and 2M thiourea solution is used as hydrotropic solubilizing agent to enhance the aqueous solubilities of atorvastatin calcium in dosage forms.

 

MATERIALS AND METHODS:

A double beam UV-Visible Spectrophotometer was used. Absorption spectra of both test and standard solutions were recorded over the wavelength range of 200-400nm using 1cm quartz cell. Atorvastatin calcium was supplied as gift sample, all other chemicals and reagents used were of analytical grade.

 

Preparation of standard stock solution:

Method: 1

Accurately weighed 25mg of Atorvastatin standard powder was transfered in to 25ml volumetric flasks. dissolved in methanol and volumes were made up to the mark with same solvent, from the above solutions of Atorvastatin 10ml aliquots were pipetted and transferred in to 100ml volumetric flasks diluted up to the mark with methanol to obtained final solutions of 100µg/ml.

 

Method: 2 and 3

For hydrotropic solubilization 20mg of pure atorvastatin calcium was dissolved in 50ml of 2.0M urea/ thiourea solution and stirred for 15 minutes and the final volume of both solutions was made up to 100ml with distilled water, the solution was filtered through whatmann filter paper No 41, this solution was further diluted with distilled water to prepare working concentrations of 100mg/ml of atorvastatin calcium.

 

Detection of absorption maxima:

For the selection of analytical wavelength, standard stock solution of atorvastatin calcium prepared was scanned in the (range of 200 to 400nm in 1cm cell) against suitable solvent as blank. The UV spectrum obtained exhibits absorption maxima (λmax) at 246nm (method 1) 240nm (method 2 and 3)

 

Preparation of sample solution:

Method:1

Twenty tablets were accurately weighed, their mean weight was determined and were ground to fine powder in a glass mortar. An amount of powdered mass equivalent to 25mg of atorvastatin weighed and transferred in to conical flask. The drugs from powder were dissolved and extracted with methanol. To ensure complete extraction of drug it was sonicated for 30min. the extract was filtered through whatmann filter paper No 41, and residue was washed with methanol. The extract and washing were pooled and transferred. To a 25ml volumetric flask and diluted with methanol. The obtained solution of atorvastatin was further diluted in 25ml volumetric flask to achieve final concentration of (30µg/ml).

 

Method :2 and 3

Tablet powder equivalent to 30mg atorvastatin calcium was weighed and transferred to a 100ml volumetric flask 70 ml of 2.0M urea(or 2.0M thiourea) solution was added to the flask and stirred for 15 min to dissolve the drug and the final volume was made up to 100ml with distilled water. The solution was filtered through whatmann filter paper No.41. The filtrate was diluted suitably with distilled water to get 10 µg/ml of atorvastatin calcium.

 

RESULTS AND DISCUSSION:

The wavelength of absorption maxima were determined for drug Atorvastatin calcium showed maximum absorbance at 246nm (method 1), 240nm (method 2 and 3)

 

Calibration Plot of Absoprtion Maxima

 

Calibration curve:

 

METHOD 1

Standard calibration curve for atorvastatin, covering the range 5-35 µg/ml, prepared by serial dilution with methanol for pure drug and tablet formulation were developed and validated. The procedure was adopted as per desired protocol. The calibration was obtained by plotting absorbance V/s Analyte concentration. The slope and intercept of the calibration line was determined by linear regression. The optical characteristics (table 1) and data related to SD and RSD are given in table 2.

Table: 1

S. NO

Optical characteristics

Method.1.

 1

Absorption maxima(nm)

247

 2

Linearity range (µg/ml)

5-35

 3

Standard regression equation

Y=0.039x+0.015

 4

Correlation coefficient(r2)

r2 = 0.998

 5

Accuracy (% recovery)

99.71 to 99.92

 6

Precision

 

 7

LOD and LOQ

0.998,3.025

 

Table: 2

Atorvastatin calcium (µg/ml)

 Intra-assay precision

Intra –assay precision

Mean ± S.D

% RSD

Mean ± S.D

% RSD

 10

99.73 ± 0.3215

0.32

99.81 ± 0.2762

 0.28

 15

99.37 ± 0.3215

0.32

100.33 ± 0.9802

 0.98

 25

99.57 ± 0.6486

0.65

 99.28 ± 0.9302

 0.94

 

METHOD.2.

Quantitative estimation of poorly water-soluble drugs involves use of organic solvents. Major drawbacks of organic solvents include high cost, volatility and toxicity. In the present investigation, hydrotropic solubilization is employed to enhance the aqueous solubilities of poorly water- soluble atorvastatin calcium in tablet dosage forms. The results of solubility studies indicated that enhancement in aqueous solubility of atorvastatinn calcium in 2.0 M urea solution and was more than 6-7 folds as compared to their solubilities in distilled water. Therefore, this solution was employed to extract atorvastatin calcium from the fine powder of tablet formulation and thus analysis will become easier one. The optical characteristic are given in the table 3

 

Table: 3 OPTICAL CHARACTERISTICS

Optical characteristics

Method 2

Beer’s law limit (µg/ml)

5 -45

Regression equation

Abs =A+B* Conc.

Slope (B)

0.0317

Intercept (A)

0.0998

Correlation coefficient

0.9999

 

METHOD .3.

To enhance the solubility of atorvastatin in water 2.0 M thiourea is employed. Under the experimental conditions described, calibration curve, precision and recovery studies were performed. The drugs obey beer’s law in the concentration range 5-45µg/ml for atorvastatin for all the methods with good correlation co-efficient 0.994 and 0.996 respectively. The results of commercial formulation analysis are presented. The accuracy and reproducibility is evident from the data as results are close to 100% and low standard deviation. Optical characteristics are given in table 4 and analyzing of pharmaceutical formulation are given in table 5 and 6.

 

Table: 4 OPTICAL CHARACTERISTICS

Optical characteristics

Method 3

Beer’s law limit (µg/ml)

5 -50

Regression equation

Abs =A+B* Conc.

Slope (B)

0.0312

Intercept (A)

0.0994

Correlation coefficient

0.9994

 

Table: 5

Atorvastatin calcium (µg/ml)

 Intra-assay precision

Intra –assay precision

Mean ± S.D

% RSD

Mean ± S.D

 % RSD

 10

99.73 ± 0.3215

0.32

99.81 ± 0.2762

 0.28

 15

99.37 ± 0.3215

0.32

100.33 ± 0.9802

 0.98

 25

99.57 ± 0.6486

0.65

 99.28 ± 0.9302

 0.94

 

 

Table :6 Analysis of pharmaceutical formulations

Methods

Labeled amount (mg)

Amount recovered (mg)

% drug recovered

Mean

Standard deviation

% RSD

Method.1

10

9.782

97.82

 

9.794

 

0.1065

 

1.087

Method.2

10

9.694

96.94

Method.3

10

9.906

99.06

 

 

CONCLUSION:

The proposed spectrophotometric method is found to be accurate, precise, economic and rapid for estimation of atorvastatin calcium. It satisfactorily eliminates interference from excipients. Hence it can be employed for routine analysis of drugs in marketed formulations in quality control laboratories. The most striking feature of this method is its simplicity, economy rapidity and non-requiring consuming sample preparations such as extraction of solvents, heating, degassing which are needed for HPLC procedure. It could be concluded that the proposed procedures are simple, do not require sophisticated techniques or instruments.

 

REFERENCES:

1.      H.W. Darwish, S.A. Hassan, M.Y. Salem, et al., Three different spectrophotometric methods manipulating ratio spectra for determination of binary mixture of amlodipine and atorvastatin, Spectrochim. Acta, part A 83 (1) (2011) 140-148.

2.      L. Joseph, M. George, B.V.R. Rao, Simultaneous estimation of atorvastatin and ramipril by RP –HPLC and spectroscopy, Pak J. Pharm. Sci. 21 (3) (2008) 282 -284.

3.      Y. Kiya, S. Miura, B. Zhang, et al., effect of levothyroxine on total lipid profiles as assessed by analytical capillary isotacho-phoresis in a patient with hypothyroidism, Endocrinal. J. 53 (6) (2006) 865-868.

4.      E. Guihen, G.D. Sisk, N.M. Scully, et al., Glenon, Rapid analysis of atorvastatin calcium using capillary electrophoresis and microchip electrophoresis, Electrophoresis 27 (12) (2006) 2338-2347.

5.      M.A. Korany, I.I. Hewala, K.M. Abdel-Hay, Determination of etofibrate, fenofibrate, and atorvastatin in pharmaceutical preparations and plasma using differential pulse polarographic and square wave voltammetric techniques, J. AOAC Int. 91 (5) (2008) 1051-1058.

6.      G. Bahrami, B. Mohammadi, S. Mirzaeei, et al., Determination of atorvastatin in human serum by reversed – phase high –performance liquid chromatography with UV detection, J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 826 (1-2) (2005) 41-45.

7.      Y. Shah, Z. Iqbal, L. Ahmad, et al., Simultaneous determination of rosuvastatin and atorvastatin in human serum using RP-HPLC/UV detection: method development, validation and optimization of various experimental parameters, J. Chromatogr. B Anal.Technol. Biomed. Life sci. 879 (9-10) (2011) 557-563.

8.      R. Petkovska, c. cornett, A. Dimitrovska, Analytical Letters 41 (2008)992-1009.

9.      S. Mazurek, R. Szostak, Journal of pharmaceutical and Biomedical Analysis 49 (2009) 168-172.

10.   N.R. Vekariya, M.B. Patel, G.F. Patel, R.B. Dholakiya, journal of young pharmacists 1 (2009) 259.

11.   N.K. Ramadan, H.M. Mohamed, A.A. Moustafa, Analytical Letters 43 (2010) 570-581.

12.   Y.U.E. Jin, Z. Xi, Z. Yan –ling, H.E. Ying-na, Y. Han-yu, Chinese journal of pharmaceuticals (2009).

13.   T. Sivakumar, R. Manavalan, C. Muralidharan, K. Valliappan, journal of separation science 30 (2007)3143-3153.

14.   S. Riahi, M.R. Ganjali, E. Pourbasheer, P. Norouzi, current pharmaceutical analysis 3 (2007)268-272.

15.   P. Mishra, A. Gupta, K. Shah, Indian journal of pharmaceutical sciences 69(2007)831.

16.   R. Sahu, V.B. Patel, Indian Journal of Pharmaceutical Sciences 69 (2007)110.

17.   M.M. Hefnawy, M. Sultan, H. Al- Johar, Journal of Liquid Chromatography and Related Technologies 32 (2009) 2923-2942.

18.   B.G. Chaudhari, N.M. Patel, P.B. Shah, Indian drugs-Bombay 43(2006)649.

19.   Zarghi A., Shafaati A., Foroutan S.M. and Khoddam A., A simple and rapid HPLC Method for the determination of atorvastatin in human plasma with UV detection and its application to pharmacokinetic studies, Arzeimittelforschung., 2005, 55,451-454.

20.   Bahrami G., Mohammadi B., Mirzaeei S. and kiani A., Determination of atorvastatin in human serum by reversed-phase high-performance liquid chromatography with UV detection, J. Chromatogra. B, 2005, 826, 41-45.

21.   Syed Najmul Azmi et al, HPLC –UV method for the determination of atorvastatin calcium in pharmaceutical formulation, Journal of New Developments in Chemistry, 1(3),38,2017

22.   Pooja A Chawla et al, Various analytical methods for analysis of atorvastatin; A review. Journal of Drug Delivery and Therapeutics. Vol no.9, No.3, May-June 2019

 

 

 

Received on 06.02.2020       Modified on 07.03.2020

Accepted on 29.03.2020      ©Asian Pharma Press All Right Reserved

Asian J. Pharm. Ana. 2020; 10(2):77-80.

DOI: 10.5958/2231-5675.2020.00013.7